An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins - PubMed (original) (raw)

An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins

Q J Zhang et al. Proc Natl Acad Sci U S A. 1993.

Abstract

T lymphocytes recognize their antigenic targets as peptides associated with major histocompatibility complex molecules. The HLA-A11 allele, a preferred restriction element for Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocyte responses, presents an immunodominant epitope derived from the EBV nuclear antigen 4. Subpicomolar concentrations of a synthetic nonamer peptide, IVTDFSVIK, corresponding to amino acids 416-424 of the EBV nuclear antigen 4 sequence, can sensitize phytohemagglutinin-stimulated blasts to lysis by EBV-specific HLA-A11-restricted cytotoxic T-lymphocytes. We show that micromolar concentrations of this peptide induce assembly and surface expression of HLA-A11 in an A11-transfected subline of the peptide transporter mutant cell line T2. Using the IVTDFSVIK peptide and a series of synthetic nonamer peptides, differing from the original sequence by single amino acid substitutions, we have defined a motif for HLA-A11-binding peptides. This predicts the presence of a hydrophobic amino acid in position 2, amino acids with small side chains in positions 3 and 6, and a lysine in position 9. Using this motif, we have identified a peptide in the carboxyl-terminal end of wild-type p53, ELNEALELK, which is able to induce HLA-A11 assembly as efficiently as the IVTDFSVIK viral peptide.

PubMed Disclaimer

Similar articles

• Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.
  Gavioli R, Kurilla MG, de Campos-Lima PO, Wallace LE, Dolcetti R, Murray RJ, Rickinson AB, Masucci MG. Gavioli R, et al. J Virol. 1993 Mar;67(3):1572-8. doi: 10.1128/JVI.67.3.1572-1578.1993. J Virol. 1993. PMID: 7679748 Free PMC article.
• Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides.
  Reali E, Guerrini R, Giori B, Borghi M, Marastoni M, Tomatis R, Traniello S, Masucci MG, Gavioli R. Reali E, et al. Clin Exp Immunol. 1996 Aug;105(2):369-75. doi: 10.1046/j.1365-2249.1996.d01-744.x. Clin Exp Immunol. 1996. PMID: 8706347 Free PMC article.
• Effect of anchor residue modifications on the stability of HLA-A11/peptide complexes.
  Gavioli R, Zhang QJ, Marastoni M, Guerrini R, Reali E, Tomatis R, Masucci MG, Traniello S. Gavioli R, et al. Biochem Biophys Res Commun. 1995 Jan 5;206(1):8-14. doi: 10.1006/bbrc.1995.1002. Biochem Biophys Res Commun. 1995. PMID: 7818553
• Transformation-associated Epstein-Barr virus antigens as targets for immune attack.
  Masucci MG, Gavioli R, de Campos-Lima PO, Zhang QJ, Trivedi P, Dolcetti R. Masucci MG, et al. Ann N Y Acad Sci. 1993 Aug 12;690:86-100. doi: 10.1111/j.1749-6632.1993.tb43999.x. Ann N Y Acad Sci. 1993. PMID: 7690218 Review. No abstract available.
• Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis.
  Moss DJ, Misko IS, Sculley TB, Apolloni A, Khanna R, Burrows SR. Moss DJ, et al. Springer Semin Immunopathol. 1991;13(2):147-56. doi: 10.1007/BF00201465. Springer Semin Immunopathol. 1991. PMID: 1724100 Review. No abstract available.

Cited by

• Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations.
  Chu PG, Chang KL, Chen WG, Chen YY, Shibata D, Hayashi K, Bacchi C, Bacchi M, Weiss LM. Chu PG, et al. Am J Pathol. 1999 Sep;155(3):941-7. doi: 10.1016/S0002-9440(10)65193-0. Am J Pathol. 1999. PMID: 10487851 Free PMC article.
• HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.
  Midgley RS, Bell AI, Yao QY, Croom-Carter D, Hislop AD, Whitney BM, Chan AT, Johnson PJ, Rickinson AB. Midgley RS, et al. J Virol. 2003 Nov;77(21):11507-16. doi: 10.1128/jvi.77.21.11507-11516.2003. J Virol. 2003. PMID: 14557636 Free PMC article.
• MHC ligands and peptide motifs: first listing.
  Rammensee HG, Friede T, Stevanoviíc S. Rammensee HG, et al. Immunogenetics. 1995;41(4):178-228. doi: 10.1007/BF00172063. Immunogenetics. 1995. PMID: 7890324 Review. No abstract available.
• An analysis of the antigen binding site of RT1.Aa suggests an allele-specific motif.
  Thorpe CJ, Moss DS, Powis SJ, Howard JC, Butcher GW, Travers PJ. Thorpe CJ, et al. Immunogenetics. 1995;41(5):329-31. doi: 10.1007/BF00172160. Immunogenetics. 1995. PMID: 7721357 No abstract available.
• The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.
  Micheletti F, Bazzaro M, Canella A, Marastoni M, Traniello S, Gavioli R. Micheletti F, et al. Immunology. 1999 Mar;96(3):411-5. doi: 10.1046/j.1365-2567.1999.00707.x. Immunology. 1999. PMID: 10233722 Free PMC article.

References

1. 1. Methods Enzymol. 1977;47:578-617 - PubMed
2. 1. Int Immunol. 1992 Nov;4(11):1283-92 - PubMed
3. 1. Tissue Antigens. 1982 Sep;20(3):161-71 - PubMed
4. 1. Int J Cancer. 1984 Feb 15;33(2):239-43 - PubMed
5. 1. EMBO J. 1986 May;5(5):943-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Immune Epitope Database and Analysis Resource

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal